does a glp 1 burn fat Weight loss with GLP-1 medicines not result in disproportionate loss of muscle mass or function in obese mice and humans The Ultimate Guide to Fat

Interestingly, a triple GLP-1/GIP/glucagon receptor agonist was found to have neuroprotective effects on a transgenic mouse model of Alzheimers disease, as drug treatment increased neurogenesis and reversed memory deficit

The DPP-4 inhibitor CV safety outcome trials have unequivocally demonstrated that DPP-4 inhibition is not associated with any increased risk of major adverse CV events (MACE), with the four trials so far published (124127) having hazard ratios (HR) for the primary outcome of between 0.96 and 1.02 (Table 2)

T., Bickel, W

Eligibility criteria included at least one weight-related comorbidity associated with overweight or obesity